West Nile encephalitis (WNE) is one of the illnesses caused by West Nile virus (WNV) infection. Most individuals infected with WNV are asymptomatic, some develop West Nile fever, and a small percentage develop neuroinvasive disease. WNV is transmitted to humans mainly via mosquito bites. The incubation period ranges from 2 days to 2 weeks [1]. WNE can present in a number of ways, albeit similar to other types of viral encephalitis. Patients usually have a fever, headache, and altered mental status.

Initial symptoms and signs of illness may include myalgia, arthralgia, or pharyngitis and are often nonspecific. Those at the extremes of age have more pronounced symptoms. Aseptic meningitis may occur simultaneously with encephalitis, resulting in signs of meningism. The severity of illness is proportional to the extent of viral invasion. Changes in the mental status range from acute confusion to coma.

Gastrointestinal upset (nausea and vomiting) is common. Gait instability, coarse tremor, and bulbar palsy have been described [2]. Less frequently reported are seizures and cerebral edema [3]. Parkinsonism, extrapyramidal manifestations, myoclonus, and muscle weakness mimicking lower motor neuron lesions, also form part of the clinical picture [4].

WNE could present with acute flaccid paralysis, which is also directly caused by WNV infection. The presence of muscle weakness distinguishes WNE from other encephalitides. Facial nerve palsies present acutely or over the course of a few weeks [5]. Elderly individuals are at an increased risk [6].

Further presenting features of WNE are ophthalmologic manifestations, lymphadenopathy (especially of the submental nodes), and a maculopapular rash on the trunk [5].

The main diagnostic test for WNV infection is the IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) [7]. IgM antibodies may be detected in serum, however, when they are present in cerebrospinal fluid (CSF) this indicates central nervous system (CNS) invasion by the virus (as IgM does not cross the blood-brain barrier). Eventually, this confirms the diagnosis of West Nile encephalitis. The majority of patients will test positive at the time of presentation [8]. Moreover, nearly all patients are MAC-ELISA positive after a week of symptomatic illness.

Immunological assays may be supplemented by the use of nucleic acid amplification test (NAAT), thus improving the detection rate to over 90%. One advantage that NAAT has over immunology is that it can detect viral infection even in immunosuppressed patients who may produce a scarce amount of antibodies.

Raised white blood cell count may be a feature of WNE, although it is not always present. Increased leukocytes, either neutrophils or lymphocytes, and elevated protein level are some of the CSF findings [9]. T2-weighted magnetic resonance imaging (MRI) may sometimes reveal brainstem and periventricular lesions [10] [11].

There is no specific antiviral treatment for West Nile Encephalitis. Management focuses on supportive care to relieve symptoms and prevent complications. This may include hospitalization for severe cases, where patients receive intravenous fluids, pain relief, and respiratory support if needed. In some instances, corticosteroids may be used to reduce brain inflammation. Rehabilitation therapies, such as physical and occupational therapy, can aid recovery in patients with neurological impairments.

The prognosis for West Nile Encephalitis varies. Many individuals recover fully, especially those with mild symptoms. However, severe cases can result in long-term neurological damage or even be fatal. Recovery may take weeks to months, and some patients may experience persistent symptoms like fatigue, muscle weakness, or cognitive difficulties. The risk of severe outcomes is higher in older adults and those with pre-existing health conditions.

West Nile Encephalitis is caused by the West Nile virus, a member of the Flavivirus genus. The virus is primarily transmitted to humans through the bite of infected mosquitoes, particularly the Culex species. Birds serve as the main reservoir hosts, and mosquitoes become infected when they feed on infected birds. Humans and other mammals are considered incidental hosts, as they do not contribute to the transmission cycle.

West Nile virus is found in many parts of the world, including Africa, Europe, the Middle East, North America, and West Asia. The virus was first identified in Uganda in 1937 and has since spread globally. In the United States, West Nile virus activity is most common during the summer and early fall. The incidence of West Nile Encephalitis varies by region and year, influenced by factors such as climate, mosquito populations, and bird migration patterns.

Once transmitted through a mosquito bite, the West Nile virus replicates in the skin and spreads to the lymph nodes and bloodstream. In some cases, the virus crosses the blood-brain barrier, leading to inflammation of the brain and surrounding tissues. The immune response to the virus can contribute to the neurological damage seen in severe cases. The exact mechanisms by which the virus causes encephalitis are not fully understood but involve both direct viral effects and immune-mediated damage.

Preventing West Nile Encephalitis involves reducing exposure to mosquito bites. This can be achieved by using insect repellent, wearing long-sleeved clothing, and staying indoors during peak mosquito activity times (dusk and dawn). Eliminating standing water around homes can help reduce mosquito breeding sites. Community-wide mosquito control programs, such as spraying insecticides, can also be effective in reducing the risk of infection.

West Nile Encephalitis is a serious neurological condition caused by the West Nile virus, transmitted through mosquito bites. While most infections are asymptomatic or mild, severe cases can lead to significant neurological complications. Diagnosis involves clinical evaluation and laboratory testing, and treatment focuses on supportive care. Prevention strategies are crucial in reducing the risk of infection, particularly in areas where the virus is prevalent.

If you suspect you or someone you know may have West Nile Encephalitis, it is important to be aware of the symptoms and seek medical evaluation. Mild symptoms may include fever, headache, and body aches, while severe cases can present with confusion, muscle weakness, and seizures. Protecting yourself from mosquito bites is key to preventing infection. Use insect repellent, wear protective clothing, and eliminate standing water around your home to reduce mosquito breeding.

1. Mostashari F,Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;358(9278):261–264.
2. Bode AV, Sejvar JJ, Pape WJ, Campbell GL, Marfin AA. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis. 2006;42(9):1234–1240.
3. Sayao AL, Suchowersky O, Al-Khathaami A, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci. 2004;31(2):194–203.
4. Pepperell C, Rau N, Krajden S, et al. West Nile virus infection in 2002. CMAJ. 2003;168(11):1399–1405.
5. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174–1179.
6. Hayes EB, Komar N, Nasci RS, Montgomery SP, O’Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1167–1173.
7. Roehrig JT, Nash D, Maldin B, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis. 2003;9(3):376–379.
8. Tilley PA, Fox JD, Jayaraman GC, Preiksaitis JK. Nucleic acid testing for West Nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis. 2006;193(10):1361–1364.
9. Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-DeMasters BK. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66(3):361–365.
10. Gyure KA. West Nile virus infections. J Neuropathol Exp Neurol. 2009;68(10):1053–1060.
11. Ali M, Safriel Y, Sohi J, et al. West Nile virus infection: MR imaging findings in the nervous system. AJNR Am J Neuroradiol. 2005;26(2):289–297.